Kyrgyzstan

Population 2018: 6.3 million

<table>
<thead>
<tr>
<th>Estimates of TB burden, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>7.3 (6.2–8.4)</td>
<td>116 (99–134)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>0.22 (0.17–0.26)</td>
<td>3.4 (2.7–4.2)</td>
</tr>
<tr>
<td>MDR/RR-TB incidenceºº</td>
<td>3 (2.4–3.6)</td>
<td>47 (39–57)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>0.39 (0.36–0.42)</td>
<td>6.2 (5.8–6.7)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.035 (0.025–0.047)</td>
<td>0.56 (0.4–0.75)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- % tested with rapid diagnostics at time of diagnosis: 62%
- % with known HIV status: 100%
- % pulmonary: 79%
- % bacteriologically confirmedººº: 61%
- % children aged 0-14 years: 4%
- % women: 39%
- % men: 57%

Total cases notified: 7 585

Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2018: 87% (75–100)
- TB case fatality ratio (estimated mortality/estimated incidence), 2018: 6% (5–7)

Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance ººº: 90%
- Laboratory-confirmed cases*: MDR/RR-TB: 1 685, XDR-TB: 137
- Patients started on treatment**: MDR/RR-TB: 1 282, XDR-TB: 105
- MDR/RR-TB cases tested for resistance to second-line drugs: 924

TBpreventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 80%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 24% (22–26)

% of MDR/RR-TB cases started on second-line treatment in 2016: 53% (1 232)
% of XDR-TB cases started on second-line treatment in 2016: 15% (68)

TB financing, 2019

National TB budget (US$ millions): 19
Funding source: 60% domestic, 40% international, 0% unfunded

º Ranges represent uncertainty intervals
ºº MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
ººº Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2020-03-19 Data: www.who.int/tb/data